PharmAust and LUMC will now progress the antiviral development program to testing in human cells.
MPLS shows antiviral activity reaching 95%.
GMP-quality MPL production for human clinical trials has commenced at Syngene International Ltd (India).
PAA clinical development plans remains unchanged.
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-11
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.025(10.2%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 22.0¢ | $405.6K | 1.791M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 32271 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 53448 | 2 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.025 ( 8.16 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.0¢ | 22.0¢ | 900359 | ||
| Last updated 15.56pm 30/04/2024 ? | |||||
| PAA (ASX) Chart |